Zobrazeno 1 - 4
of 4
pro vyhledávání: '"William E Janssen"'
Autor:
Janelle Perkins, Lynn C. Moscinski, Karen K. Fields, G. J. Elfenbein, William E. Janssen, W L Trudeau
Publikováno v:
Journal of Clinical Oncology. 14:1868-1876
PURPOSE The present study evaluates the clinical significance of detection of cytokeratin 19 (K19) in the bone marrow of patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous bone marrow transplantation (ABMT). PATIENTS
Autor:
Alberto Chiappori, Dmitry I. Gabrilovich, Sunil Chada, S.J. Antonia, Noweeda Mirza, M. Dunn, William E. Janssen, M. Sereno, Renee Smilee, Kerstin B. Menander
Publikováno v:
Journal of Clinical Oncology. 25:3012-3012
3012 Background: Although ES-SCLC is initially, very responsive to CT, responses are not durable and relapse is characterized by chemoresistance. High incidence of p53 gene mutations, which prolong the protein’s half life, result in its frequent ov
Autor:
Alberto Chiappori, Kerstin B. Menander, Sunil Chada, S.J. Antonia, Dmitry I. Gabrilovich, Noweeda Mirza, M. Dunn, William E. Janssen, M. Willis, Renee Smilee
Publikováno v:
Journal of Clinical Oncology. 23:2543-2543
2543 Background: Many types of cancer are associated with mutations in the p53 gene. Patients with SCLC exhibit a very high frequency of p53 mutations, which result in overexpression of p53 protein in tumor cells. In preclinical studies we and others
Autor:
M. Dunn, Patricia A. Thompson, J. Pow Sang, William E. Janssen, David Noyes, M. J. Farmelo, John D. Seigne, S.J. Antonia, Renee Smilee, Mayer Fishman
Publikováno v:
Journal of Clinical Oncology. 23:4502-4502
4502 Background: Since efficacy of subcutaneous interleukin-2 (IL-2) is limited in RCC, novel treatments are needed. The protein B7–1 is normally not expressed by RCC cells, so forced expression could increase tumor cell immunogenicity by providing